Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM512 in moderate-to-severe atopic dermatitis
CTR20251647Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started Jun 2025; status: active.
02
Drugs
CM512
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20251647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251647.